ALKS

Announcements

Nothing here yet

Daily updates

• Alkermes reported positive Phase 1b proof-of-concept data for ALKS 7290 in adults with ADHD, showing dose-dependent, clinically meaningful improvements in AISRS and CGI-S scores with generally favorable tolerability and no serious treatment-emergent adverse events.Sep 21, 2026

FDA designations

• Alkermes Receives U.S. and European Orphan Drug Designations for Alixorexton in Narcolepsy and Idiopathic HypersomniaJun 15, 2026

News

• Alkermes reported positive Phase 1b results demonstrating clinical proof-of-concept for ALKS 7290 in adults with ADHDSep 21, 2026
• The Lancet Neurology published data from Alkermes' positive Phase 2 Vibrance-1 study of alixorexton in adults with narcolepsy type 1Aug 25, 2026
• Alkermes received orphan drug designations in the U.S. and Europe for AlixorextonJun 15, 2026
• Alkermes reports positive topline results from Phase 3 REVITALYZ study of LUMRYZMay 12, 2026
• Alkermes initiated Phase 3 Brilliance trials of alixorexton for narcolepsyApr 1, 2026